Transfusion registry · internal status

Where the registry stands on 16 November 2026

Two years of enrolment, from the first documented administration in September 2024 to the export of 16 November 2026.

1,001
patients registered
consent recorded in the registry
3,218
blood product administrations
documented across 10 product types
647
transfused patients
at least one product documented
108
patients with follow-up
144 questionnaires in a window: 79 at 3 months, 65 at 1 year
Analysed with the published registry pipeline1 / 8

Patients

Enrolment and documentation since September 2024

Cumulative blood product administrations by month

Documented administrations with a date, September 2024 to November 2026. The last month covers 1 to 16 November only.

647
transfused patients
65% of all registered
354
registered without products
consent only, so far
66
median age, years
IQR 59 to 73
69%
male
of patients with documented sex
Age and sex refer to the 647 transfused patients. Busiest month so far: January 2026 with 250 administrations.2 / 8

Blood products

3,218 administrations across ten product types

Administrations by product

Count and share of all 3,218 documented administrations.

984
red blood cell concentrates
31% of all administrations
831
albumin
26%
5.0
administrations per patient, mean
median 2, IQR 1 to 4.5
98.8%
of administrations with a dosage
RBC 98.9%, albumin 100%, PPSB 99.4%
Cell salvage counts each documented run as one administration. Iron i.v. and oral iron are shown together.3 / 8

Clinical context

Diagnoses, procedures and indications

Diagnoses and procedures are coded in SNOMED CT, and red cell transfusions are documented with guideline-based indication categories.

Indications for red cell transfusion

Share of the 835 red cell administrations with a documented indication (85% of 984).

93.6%
of administrations with a primary diagnosis
178 different SNOMED CT codes
70.8%
with a procedure
125 different SNOMED CT codes

Most frequent primary diagnoses

  1. Coronary arteriosclerosis91 patients
  2. Aortic valve stenosis69 patients
  3. Mitral valve disorder37 patients

Most frequent procedures

  1. Replacement of aortic valve108 patients
  2. Replacement of mitral valve58 patients
  3. Bypass graft35 patients
Patients counted once per code. Only codes documented for at least 10 patients are listed.4 / 8

Sex-sensitive analysis · treatment

Product mix by sex

Shares refer to registry patients who received at least one blood product, a small and selected group, not to all patients treated at the hospital.

Share of patients receiving each product, by sex

Men (n = 447) and women (n = 199) with at least one blood product. A patient can receive several products.

menwomen
447 | 199
men | women with a blood product
basis for every sex-stratified view
7.54 | 7.62
g/dl mean hemoglobin before red cells, women | men
n = 335 | 587
12 | 13.5
g/dl lower normal limit, women | men
sex-specific reference ranges applied
2 | 2
median administrations per patient, women | men
IQR 1 to 5 and 1 to 4
Patients without documented sex are excluded. Oral iron is not shown by sex because one group is below 3. Descriptive, not adjusted for age, procedure or indication.5 / 8

Sex-sensitive analysis · laboratory values

Women and men start from similar lab values

Means of paired measurements of each product's primary lab parameter, before (open circle) and after (filled circle) administration, by sex. 1,659 pairs in total.

menwomenbeforeafternormal range
Pairs stratified by sex with the pipeline's own lab normalisation and sex assignment; men and women add up to the overall paired counts. Hemoglobin normal range 12 to 16 g/dl for women, 13.5 to 17.5 g/dl for men. Scales do not start at zero.6 / 8

Sex-sensitive analysis · dose

Dose normalised to body size, by sex

Doses are recorded per administration and normalised to body weight or estimated blood volume. Mean absolute dose per red cell administration: 364 ml in women, 423 ml in men. Normalised medians are higher in women for all seven products.

menwomen
Medians per administration. Red cells and plasma per litre of estimated blood volume (EBV, Nadler formula), all other products per kg body weight.7 / 8

Join the registry

Track your blood product usage, treatment regimens and patient outcomes

Be part of a global network. Every partner site gets the views in this report for its own patients, and contributes to a shared long-term picture of transfusion.

Blood product usage

Ten product types, dosage per administration, monthly volumes and data completeness.

Treatment regimens

Indications, paired lab values before and after, doses normalised to body size, every view by sex.

Patient outcomes

Patient-reported physical capacity and frailty at 3 months and 1 year, compared with the baseline at treatment. 108 patients have answered so far.

Milestone paper

A Web-Based Registry Framework Linking Transfusion Practice to Long-Term Patient Outcomes: Design and Single-Center Feasibility Study

Nürenberg-Goloub E, Friedrichson B, Nordine M, Storf H, Zacharowski K, Kloka JA. Journal of Medical Systems 50, 153 (2026). doi:10.1007/s10916-026-02474-2

Read the paper in the Journal of Medical Systems →
Figures in this report: export of 16 November 2026, analysed with the published registry pipeline. Descriptive only; counts below 3 are not shown.8 / 8
1 / 8